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Abstract 
Background: We aimed to determine the effect of lavandula angustifolia essential oil (LEO) on IL-23 and brain-
derived neurotrophic factor (BDNF) gene expressions in peripheral blood mononuclear cells (PBMCs) of relapse-
remitting MS (RRMS) patients. Materials and Methods: LEO was prepared using the hydrodistilation method on 
the plants aerial parts.    8 female RRMS patients and 8 healthy sex and age matched controls were entered into this 
study. PBMC cells were separated using Ficoll method and were treated with a concentration of 225 µg/ml LEO 
which and then the mRNAs were used for determining the effects of LEO on IL-23 and BDNF gene expressions 
using Quantitative Real Time PCR technique. Moreover in order to determine the anti-inflammatory effects of LEO, 
we measured the gene expression of IL-6 and IL-23 in stimulated healthy PBMC cells treated with LEO. Results: 
Results showed that there is no significant difference between PBMC of patients compared to healthy controls in 
case of IL-23 gene expression. Moreover, LEO has no significant effect on gene expression of IL-23 in PBMC of 
neither patients nor control. Also the results showed that BDNF gene expression is reduced to 41% compared to 
healthy controls and LEO can increase the BDNF gene expression by 81% in patients PBMCs. Moreover we 
observed that LEO can significantly reduce the LPS stimulated IL-6 gene expression in healthy PBMCs but had no 
significant effect on IL-23 gene expression. Conclusion: The present study demonstrated that L.angustifolia 
essential oil may have a protective effect against neuron damage via increasing the gene expression of BDNF in 
PBMCs from RRMS patients. However, further studies are necessary to confirm our results. 
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Multiple Sclerosis (MS) is the most common 
neurological disability in youth populations around 
the world. MS has been recognized as a well-
established autoimmune disease. In spite of 
numerous efforts  to find  therapeutically approaches 
for alleviating  the disease activity and progression, 
there is no known cure for it yet (1). 
In most cases (80%), MS begins in Relapse-
Remitting (RRMS) form which presents with periods 
of relapse accompanied with clinical symptoms that 
may take days or weeks followed by periods of 
remission and recovery (2). 
Precise mechanism underlying MS is still a 
matter of discuss but current theory involves 
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inflammatory sites called lesions or plaques. 
Structurally, lesions contain multiple immune cells ( 
T cells , B cells , macrophages , plasma cells , etc. ) 
which present an autoimmune response to neuronal 
myelin sheets and subsequently result in 
demyelination and axonal loss over the course of the 
disease (3). 
Numerous factors contribute to MS 
pathogenesis as a complex disease. In recent years 
pro-inflammatory T-helper cell called TH17  has 
been identified as the  key players in 
pathomechanism of autoimmune diseases (4). 
Among many molecules that are necessary for 
producing functional Th17 cells, IL-6 , IL-21, IL-23 
and TGF-β are the most important factors (5). 
IL-23 is a heterodimer cytokine composing of 
two subunits; p19 which is exclusive to IL-23 and 
p40 which is shared with IL-12 (6).  
It has been shown that IL-23 is necessary for 
experimental autoimmune encephalomyelitis (EAE) 
pathogenesis and it is also critical for Th17 
polarization and the acquisition of 
encephalitogenicity during EAE(7, 8). IL-23 level is 
elevated in both serum and CSF of MS patients and it 
is also a validated biomarker for MS (9-12). 
Brain-Derived Neurotrophic Factor (BDNF ) 
is a member of neurotrophin family which is 
primarily produced not only by neurons but also by 
immune cells (13). There are two functional forms of 
BDNF; pro-BDNF and mature BDNF. Pro-BDNF 
binds to p75 receptor and induces neuronal apoptosis, 
but mature BDNF binds to tyrosine receptor kinase B 
(TrkB) and is associated with neuronal survival and 
differentiation and synaptic plasticity (14-17). 
There is also evidence that  BDNF is 
associated with a number of neurological diseases 
such as Huntington’s disease , Alzheimer’s disease , 
Parkinson’s disease and also psychiatric diseases 
(18). 
Studies have shown that BDNF production is 
reduced in MS lesions and are instead being 
produced by activated immune cells in the area (19). 
Studies have shown differences in BDNF levels of 
MS patients with healthy population including 
decreased BDNF levels in SPMS and RRMS patients 
in remission and also increased BDNF levels in 
RRMS patients in relapse period which may be 
related to ameliorating the CNS damage caused by MS 
attacks (18). 
Lavender has long been used as a therapeutic 
herb in traditional medicine and has been used as an 
antibacterial, antifungal, analgesia, anti-depressant, 
antispasmodic, sedative, anti-inflammatory agent (20). 
Lavender essential oil (LEO) has more than 100 
constituents but the most prominent components of 
LEO are Linalool and linalyl acetate which are 
considered to have the prominent role in LEO’s 
biological effects (21). 
It has been shown that LEO and linalool can 
modulate the CNS neurotransmission (22) and there is 
also evidence of LEO neuroprotective properties in 
cerebral injury models (23). 
The mechanism of action of most of the well-
known old and new drugs that are used to manage the 
disease progression, is based on modulating the 
immune system. Drugs such as IFN beta, Glatiramer 
acetate, Fingolimod, Daclizumab, Alemtuzumab, 
Natalizumab and Ocrelizumab all change the disease 
progression through either reducing the immune cell 
count or reducing the pro-inflammatory cytokine 
production and efficacy (24). There is accumulating 
evidence addressing the beneficial anti-inflammatory 
effects of LEO and its constituents as they have been 
shown to modulate different inflammatory factors such 
as IL-6, TNF-α, MIP-2, IL-1β, TRL4, NF-κB, TNF-α 
and MCP-1 (25-27), however there is no study 
evaluating the LEO effects on regulation of 
inflammatory pathways in peripheral blood monocular 
cells. Hence, we were encouraged to determine the 
effects of LEO on PBMC gene expression of IL-23 
and BDNF in MS. 
Methods 
Study Groups .The patients group was 
consisted of 8 women with relapse remitting multiple 
sclerosis (RR-MS) that were diagnosed at Firoozgar 
Hospital affiliated by Iran University of Medical 
Sciences,Tehran,Iran. Patients didn’t have any other 
disease prior to the diagnosis of MS. Blood samples 
were collected before administration of drug. The 
control group was consisted of 8 healthy age-matched 
women. Controls didn’t have any history of 
autoimmune disease and didn’t receive any 
immunomodulatory drugs. Patients were clinically 
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diagnosed according to McDonald criteria (2) with 
Expanded Disability Status Scale (EDSS)  between 
0-2. The study protocol was approved by the Ethics 
Committee of Tehran University of Medical 
Sciences, and written informed consent was obtained 
from all subjects. 
Isolation of PBMC and cell culture . Blood 
samples were collected in collecting tubes containing 
sodium heparin as an anti-coagulant. Isolation of 
peripheral blood mononuclear cells (PBMCs) were 
done by Lympholyte® Cell Separation Media ( 
CEDARLANE , Canada ) and the obtained cells 
were washed two times with phosphate buffered 
saline (PBS).Then total number of the isolated cells 
were counted and PBMCs at density of  4×10⁶ 
cells/well  were seeded in 6 well plates ( SPL Life 
Sciences . Korea). Culture medium used in this 
experiment was RPMI 1640 (Containing L-glutamine 
and HEPES) (Caisson Labs. USA) containing 10% 
heat inactivated fetal bovine serum (GIBCO, United 
Kingdom) and 1% penicillin/streptomycin solution. 
In order to cell stabilization, plates were 
incubated for 12h before treatment. Cells were 
treated with LEO at 225 µg/ml (equal to 0.025% 
concentration of LEO) for 24h. 
Essential oil preparation. Lavandula 
angustifolia dried aerial parts were purchased from a 
renowned local provider in Tehran. Plant was 
identified by prof. Narges Yasa, department of 
pharmacognosy in faculty of pharmacy, Tehran 
University of Medical Sciences. Essential oil was 
obtained via hydrodistiliation using a clevenger-type 
apparatus for 4h. Then it was dried with anhydrous 
sodium sulfate and was filtered with 0.22 µm syringe 
filter (Jet Bio-Filtration Co, China) and stored in the 
dark at 4 °C. 
MTT Assay. LEO was diluted in dimethyl 
sulfoxide (DMSO) in a way that the highest 
concentration contained 0.4% DMSO. Concentration 
of LEO was in following order: 450 µg/ml, 225 µg/ml, 
112.5 µg/ml, 56.25 µg/ml, 28.12 µg/ml, 14.06 µg/ml, 
7.03 µg/ml and 3.51 µg/ml. 
Assay was done in triplicate and 250×10³ Cells 
were treated with LEO and incubated for 24, 48 and 
72 h in 37 °C with 5% CO2. 
MTT (Sigma- Aldrich. USA) assay was done in 
96 well plates (SPL Life Sciences. Korea) with 4h 
incubation time. Toxicity of LEO on PBMC was 
determined with measuring the absorption of color 
produced with MTT using BioTek EON Microplate 
Reader ( BioTek Instruments, Inc  . USA) at 570nm 
wave length. 
Real Time PCR. Then cells were harvested 
with a scrapper and were immediately used for RNA 
extraction. 
Hybrid-R Blood RNA kit (GeneAll 
Biotechnology co. Seoul. Korea) was used for RNA 
extraction procedure. After the extraction, 
concentration and quality of RNA was measured with 
NanoDrop 1000 Spectrophotometer (Thermo 
Scientific. USA) and then the integrity of the extracted 
RNA was determined by 1.5% agarose gel 
electrophoresis. 
The cDNA synthesis was done with RevertAid 
First Strand cDNA Synthesis Kit (Theromo scientific. 
USA). Total concentration of RNA that was used for 
this procedure was 500ng/µl. 
Real-Time PCR was performed with SYBR 
Premix Ex Taq II (TaKaRa. Japan) using a Rotor-
Gene Q Real-time PCR Cycler (QIAGEN Hilden. 
Germany). Primers used for IL-23, IL-6 and BDNF are 
provided in Table 1. 
Determining the anti-inflammatory effects of 
the LEO on IL-6 and IL-23 gene expression. In a 
complementary assay for determining the anti-
inflammatory effects of the LEO, healthy PBMCs 
were isolated as described. 
Briefly, isolated PBMCs were pre-treated with 
Table 1. Real-Time PCR primer sequences for β-Actin, IL-6, IL-23 and BDNF 
 Forward Reverse 
IL-23 5΄AGAGGGAGATGAAGAGACTAC ΄3 5΄ GCAAGCAGAACTGACTGT 3΄ 
IL-6 5΄ ACTCACCTCTTCAGAACGAATTG 3΄ 5΄ CCATCTTTGGAAGGTTCAGGTTG 3΄ 
BDNF 5΄ CCCATTCAGCCCATTTCA 3΄ 5΄ GCTTATCCCTCACCCTACTA 3΄ 
Β-Actin 5΄ GCAAGCAGGAGTATGACGAG 3΄ 5΄ CAAATAAAGCCATGCCAATC 3΄ 
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225 µg/ml of LEO for 12h. Then cells were treated 
with 100 ng/ml concentration of Lipopolysaccharide 
(LPS) (Sigma- Aldrich. USA) for 3h (LPS 
concentration was borrowed from previous work of 
our colleagues on PBMC (28) ) and subsequently 
were collected to determine the effects of LEO on 
IL-23 and IL-6 gene expression. It should be noted 
that the final concentration of DMSO in all wells was 
0.2%. 
Results 
Study Groups. A total of 8 female RRMS 
patients and 8 healthy females were selected for this 
study. All the patients were in remission period with 
mean disease duration of 2.625 ± 0.73 years (mean ± 
SEM). All the Participant in the control group were 
at the same age group as the patients and there was 
no statistically significant difference between healthy 
and patient group in this regard (RRMS 33.25 ± 2.05 
years vs  healthy controls 29.25 ± 0.99 years , mean 
± SEM, p = 0.1).  
MTT assay. LEO toxicity was determined by 
MTT assay. We observed no significant change in 
cell viability after exposure of cells to LEO at 
concentrations of 225 µg/ml and lower for 24h, 48h 
and 72h in comparison with untreated PBMCs and 
the cell viability was more than 90% under treatment 
with these concentrations. However, the exposure of 
PBMCs with LEO at 450 µg/ml for 24h,48h and 72 h 
  significantly reduced the cell viability to 85% (p 
<0.01) , 81% (p <0.05)  and 84% respectively (p 
<0.05) (figure 1). 
Effect of LEO on IL-23 Gene expression. 
Gene expression of IL-23 was measured using 
quantitative real-time PCR method. Results shown no 
significant difference between PBMCs of RRMS 
patients and controls in case of IL-23 gene expression. 
Also LEO has shown no significant effect on IL-23 
gene expression both in RRMS patients and controls 
group (figure 2). 
Effect of LEO on BDNF Gene expression. 
Results of BDNF gene expression showed a 
significant decrease in BDNF expression level in 
PBMCs of RRMS patients compared to control group. 
BDNF expression in RRMS patients 
significantly decreased to 41% of control group 
(P<0.0001). LEO treatment for 24h resulted in 
significant increase of BDNF expression by 81% in in 
PBMC of RRMS patients (P=0.013). It was also 
shown that LEO treatment reduced BDNF gene 
expression by 34% in PBMC of control group 
(P<0.01) (figure 3). 
Effect of LEO pre-treatment on LPS induced 
IL-6 gene expression IL-23 Gene expression. Results 
of this test repeated our previous result in the case of 
IL-23. There was no significant difference in term of 
IL-23 gene expressions in LPS-treated healthy PBMCs 
compared to pre-treated group. There was also no 
significant difference between LEO –treated PBMCs 
and untreated cells regarding IL-23 gene expression. 
Results of IL-6 gene expression showed a significant 
 
 
Figure 1. Assessment of PBMCs viability in response to LEO treatment. Cells were incubated with different concentrations of LEO (from 
450µg/ml to 3.51µg/ml) for A) 24 h, B) 48 h and C) 72h and cell viability was determined by MTT assay. The MTT assay was performed in 
triplicate and data are reported from the mean of triplicates. Data are expressed as means ± SEM. 
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increase in PBMC IL-6 gene expression in LPS-only 
group compared to control (11.2 fold increase, 
P<0.01). It was also shown that LEO pre-treatment 
can significantly reduce the LPS- induced IL-6 gene 
expression to 6 fold of baseline level, P<0.05). There 
was also no significant difference between LEO-only 
group and control regarding IL-6 gene expression 
(figure 4). 
Discussion 
As a T-cell related autoimmune disease, 
immune cells play a pivotal role in MS pathology. In 
MS, Th17 cells can cross the blood-brain barrier and 
secrete inflammatory cytokines like IL-17, IL-22, 
Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and granzyme-B. Th-17 cells can facilitate 
the infiltration of other immune cells and also mediate 
inflammatory responses through neuron, astrocyte and 
microglia (29, 30). 
A number of cytokines mediate the 
differentiation of Th17 from naïve CD4⁺ T cells. TGF-
β, IL-6 and IL-21 play a key role in emerging of Th17 
from naïve T cells but it is the IL-23 which mediates 
the final differentiation and expansion process and 
production of a fully functioning Th17 cells (31). Thus 
IL-23 has been an interesting candidate in MS 
researches and it even has been considered as a 
therapeutic target (32). 
There is a number of studies that investigated 
the level of IL-23 in MS patients. Shajarian et al. 
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Figure 3. Effect of LEO on BDNF   mRNA expression in 
PBMCs from RRMS patients and healthy subjects. PBMCs were 
treated with LEO (225 µg/ml) for 24 h. All untreated cells were 
treated with 0.4 % of DMSO as a control. Data are expressed as 
mean ± SEM.(* = P<0.5, ** = P<0.01, **** = P<0.0001) 
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Figure 2. Effect of LEO on IL-23   mRNA expression in PBMCs 
from RRMS patients and healthy subjects. PBMCs were treated 
with LEO (225 µg/ml) for 24 h. All untreated cells were treated 




Figure 4.  Effect of LEO, LPS, and LEO plus LPS on mRNA expression of (A) IL-23 and (B) IL-6 in PBMCs from healthy subjects. PBMCs 
were treated as follows: untreated (only with 0.2% DMSO for 15 h); LEO  (225µg/ml) for 15 h;   LPS (100 ng/ml) for 3 h; and LEO plus LPS 
group receiving LPS  (100 ng/ml) for 3 h following 12 h pretreatment with LEO  (225µg/ml). All untreated cells were treated with 0.2% of 
DMSO as a control. Data are expressed as mean ± SEM. (* = P<0.05, ** = P<0.01) 
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measured the IL-23 serum levels of RRMS patients 
in remission period of the disease. Results showed a 
six fold increase in patients compared to controls 
(11) also wen et al . demonstrated an increased IL-
23, IL-17 and TNF-α in Chinese population with 
RRMS in remission period (12). There is also 
evidence of IL-23 presence in MS related brain 
lesions as Li et al’s study on MS brain lesion 
specimens showed an increased expression and 
production of IL-23p19 subunit in 
microglia/macrophage and dendritic cells in the 
specimens (33). 
In present study we didn’t observed any 
significant difference between PBMC gene 
expression of IL-23 in patient and control group. 
Although our result is in contrast with the 
majority of studies regarding the connection between 
IL-23 and MS, there is also evidence supportive of 
our findings. Hasheminia et al.  studied the 
inflammatory and anti-inflammatory cytokines in 
newly diagnosed RRMS patients that were in relapse 
stage of the disease and didn’t find any statistically 
significant difference between PBMC gene 
expression and serum level of IL-23 between patient 
and controls (34). 
Contradiction between the results of 
Hasheminia et al and our work with other studies that 
showed increased IL-23 production in MS patients 
might be due to differences in disease duration in 
patient group among these studies. As in Hasheminia 
et al’s study only newly diagnosed patients were 
enrolled and in our study the disease duration was 
just 2.6 years while patients enrolled in other studies 
had a well stablished disease with several years of 
duration. 
After LEO treatment we didn’t see any 
significant difference between PBMC IL-23 gene 
expression neither in patient nor in control group. 
This was a disappointing result as the anti-
inflammatory effects of lavender is scientifically 
stablished by several studies. Algieri et al 
investigated the anti-inflammatory effects of 
Lavandula stoechas and Lavandula dentate in murine 
epithelial cells and also BMDM cells and results 
shown a significant reduction in IL-6, TNF-α and 
MIP-2 gene expression (25). Also Huang et al 
showed a significant reduction in IL-1β and TRL4 
production and NF-κB phosphorylation in THP-1 cells 
treated with Lavender essential oil (26).  Linalool, one 
of the most prominent constituents of LEO, also has 
the potential to reduce the production of IL-6, IL-1β, 
and TNF-α and MCP-1 and inhibition of NF-ƙB 
activation (27). 
To confirm our LEO’s anti-inflammatory 
effects we measured the gene expression levels of IL-
23 and IL-6 in LEO pre-treated PBMCs that were 
activated with LPS. Previous results were repeated and 
no significant effect was seen on IL-23 gene 
expression but LEO pre-treatment significantly 
reduced the IL-6 gene expression induced by LPS. 
This finding is in line with previous studies that seen 
an inhibitory effect on IL-6 production as a result of 
Lavender treatment (25, 27). This results confirms the 
anti-inflammatory effects of LEO but it also suggests 
that LEO mechanism of action may not affect the IL-
23 gene expression. 
BDNF is also an interesting candidate in 
multiple sclerosis researches. BDNF is a neurotrophic 
factor which plays an essential role in neuronal 
development, regeneration and plasticity (18). 
Neurons are the main producers of BDNF in CNS but 
In MS-related lesions, the BDNF production capacity 
is significantly reduced. Instead it seems that residing 
activated immune cells in the lesions can produce 
BDNF and may have a role in ameliorating the 
damage caused by MS attacks (13). 
There are multiple studies regarding the BDNF 
levels in MS patients. Azoulay et al and Urshansky et 
al have shown reduced production of BDNF in 
PBMCs of RRMS patients in remission period of the 
disease (35, 36). Also Sarchielli et al  showed 
increased levels of BDNF in RRMS patients in relapse 
period compared to patients in remission period 
suggesting the potential neuroprotective roles of 
BDNF after the MS attacks (37). There is also studies 
regarding the effects of MS treatments on BDNF 
levels. Azoulay et al.  showed augmentation  of BDNF 
to normal levels in RRMS patients treated with 
Glatiramer acetate (GA) (38). Mehrpour et al also 
showed similar results in RRMS, Secondary 
progressive MS (SPMS), Primary progressive MS 
(PPMS) and Progressive relapsing MS (PRMS) 
patients with active disease treated with Interferon-β 
(39). 
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In present study we have observed a 
significant decrease in PBMC BDNF gene 
expression levels in RRMS patients in remission 
period compared to control group which is in line 
with previous studies and suggesting a reduced 
capacity of BDNF production in MS patients. 
Effect of LEO on BDNF production is not 
very well stablished. To our knowledge there was 
only one study regarding the effects of LEO on 
BDNF production. Xu et al investigated the effects of 
Linalool and LEO in Alzheimer disease Murine 
model which the resulted in increased gene 
expression of BDNF and TrkB (40). 
Taken together, the present study showed a 
significant increase in PBMC BDNF gene expression 
of RRMS patients after LEO treatment which may 
suggest a possible neuroprotective effect of LEO 
through increasing the BDNF levels in RRMS 
patients. However, more investigations are needed to 
reach a conclusive view regarding the effects of LEO 
on BDNF production. 
Conclusion 
Based on our results it seems that L. 
angustifolia essential oil may have the potential to 
increase BDNF gene expression in PBMCs of RRMS 
patients. 
It also may have anti-inflammatory effects 
through reducing the gene expression of 
inflammatory cytokines like IL-6 although it was 
shown that it may not be effective on IL-23 gene 
expression. 
In future with the help of further studies, 
L.angustifolia may have the potential to alleviate MS 
CNS damage as a supplementary treatment. 
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